Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.

Mr. Handelman will be available for one-on-one meetings with the investment community during the conference. Please contact LD Micro organizers if you would like to arrange a meeting.

About Lion Biotechnologies

Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.genesis-biopharma.com/.

INVESTOR CONTACT:LHADon MarkleySenior Vice President310-691-7100dmarkley@lhai.com